Automated Author ProfileGluz, O.
Gluz, O.
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 2.7 (sum of 4 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
Medicine
Authors
- Ditsch, N. ;
- Untch, M. ;
- Kolberg-Liedtke, C. ;
- Jackisch, C. ;
- Krug, D. ;
- Friedrich, M. ;
- Janni, W. ;
- Müller, V. ;
- Albert, U.-S. ;
- Banys-Paluchowski, M. ;
- Bauerfeind, I. ;
- Blohmer, J.-U. ;
- Budach, W. ;
- Dall, P. ;
- Diel, I. ;
- Fallenberg, E.M. ;
- Fasching, P.A. ;
- Fehm, T. ;
- Gerber, B. ;
- Gluz, O. ;
- Hanf, V. ;
- Harbeck, N. ;
- Heil, J. ;
- Huober, J. ;
- Kreipe, H.H. ;
- Kühn, T. ;
- Kümmel, S. ;
- Loibl, S. ;
- Lüftner, D. ;
- Lux, M. ;
- Maass, N. ;
- Moebus, V. ;
- Mundhenke, C. ;
- Park-Simon, T.-W. ;
- Reimer, T. ;
- Rhiem, K. ;
- Rody, A. ;
- Schmidt, M. ;
- Schneeweiss, A. ;
- Solbach, C. ;
- Solomayer, E.-F. ;
- Stickeler, E. ;
- Thomssen, C. ;
- Witzel, I. ;
- Wöckel, A. ;
- Thill, M.
Medicine
Authors
- Ditsch, N. ;
- Untch, M. ;
- Kolberg-Liedtke, C. ;
- Jackisch, C. ;
- Krug, D. ;
- Friedrich, M. ;
- Janni, W. ;
- Müller, V. ;
- Albert, U.-S. ;
- Banys-Paluchowski, M. ;
- Bauerfeind, I. ;
- Blohmer, J.-U. ;
- Budach, W. ;
- Dall, P. ;
- Diel, I. ;
- Fallenberg, E.M. ;
- Fasching, P.A. ;
- Fehm, T. ;
- Gerber, B. ;
- Gluz, O. ;
- Hanf, V. ;
- Harbeck, N. ;
- Heil, J. ;
- Huober, J. ;
- Kreipe, H.H. ;
- Kühn, T. ;
- Kümmel, S. ;
- Loibl, S. ;
- Lüftner, D. ;
- Lux, M. ;
- Maass, N. ;
- Moebus, V. ;
- Mundhenke, C. ;
- Park-Simon, T.-W. ;
- Reimer, T. ;
- Rhiem, K. ;
- Rody, A. ;
- Schmidt, M. ;
- Schneeweiss, A. ;
- Solbach, C. ;
- Solomayer, E.-F. ;
- Stickeler, E. ;
- Thomssen, C. ;
- Witzel, I. ;
- Wöckel, A. ;
- Thill, M.
Introduction: Tumor biological factors of breast cancer (BC) such as hormone receptor (HR) status, HER2 status, and grade can differ in the metastatic cascade from primary to lymph node (LN) metastasis and to distant metastatic tissue. Systematic data regarding therapeutic consequences are yet limited. Methods: We conducted a prospectively planned, retrospective cohort study comparing BC phenotype in tissue from primary tumors (PTs), locoregional LN metastases, and disease recurrence (DR). HR and HER2 as well as tumor grade in PTs and DR were obtained by a database search. No centralized biomarker testing was performed. The impact of changes in tumor biological factors on post-recurrence survival (PRS) and overall survival was analyzed. Results: PriMet comprises 635 patients (LN tissue in 142 patients). Discrepancies for HR or HER2 status between PT and DR were observed in 18.7 and 21.6% of cases, respectively. For HR status, positivity of PT and negativity of DR was seen more often (13.2%) than vice versa (5.5%). For HER2 status, negativity of the primary and positivity of DR was seen more often (14.9%) than vice versa (6.7%). Discordance was more often observed between PT and LN metastasis compared to LN versus DR. However, numbers were small. Compared to concordant non-triple-negative (TN) disease, concordant TN disease showed significantly inferior PRS. Conclusion: We demonstrate receptor discordance to occur relatively frequently between PT, LN metastasis, and DR and to impact patient prognosis. However, clinical consequences of receptor discordance need to be drawn with caution considering clinical aspects as well as tumor biology.
Authors
- Kolberg-Liedtke, C. ;
- Wuerstlein, R. ;
- Gluz, O. ;
- Heitz, F. ;
- Freudenberger, M. ;
- Bensmann, E. ;
- DuBois, A. ;
- Nitz, U. ;
- Pelz, E. ;
- Warm, M. ;
- Ortmann, M. ;
- Sultova, E. ;
- Brucker, S.Y. ;
- Kates, R.E. ;
- Fehm, T. ;
- Harbeck, N.
Introduction: Tumor biological factors of breast cancer (BC) such as hormone receptor (HR) status, HER2 status, and grade can differ in the metastatic cascade from primary to lymph node (LN) metastasis and to distant metastatic tissue. Systematic data regarding therapeutic consequences are yet limited. Methods: We conducted a prospectively planned, retrospective cohort study comparing BC phenotype in tissue from primary tumors (PTs), locoregional LN metastases, and disease recurrence (DR). HR and HER2 as well as tumor grade in PTs and DR were obtained by a database search. No centralized biomarker testing was performed. The impact of changes in tumor biological factors on post-recurrence survival (PRS) and overall survival was analyzed. Results: PriMet comprises 635 patients (LN tissue in 142 patients). Discrepancies for HR or HER2 status between PT and DR were observed in 18.7 and 21.6% of cases, respectively. For HR status, positivity of PT and negativity of DR was seen more often (13.2%) than vice versa (5.5%). For HER2 status, negativity of the primary and positivity of DR was seen more often (14.9%) than vice versa (6.7%). Discordance was more often observed between PT and LN metastasis compared to LN versus DR. However, numbers were small. Compared to concordant non-triple-negative (TN) disease, concordant TN disease showed significantly inferior PRS. Conclusion: We demonstrate receptor discordance to occur relatively frequently between PT, LN metastasis, and DR and to impact patient prognosis. However, clinical consequences of receptor discordance need to be drawn with caution considering clinical aspects as well as tumor biology.
Authors
- Kolberg-Liedtke, C. ;
- Wuerstlein, R. ;
- Gluz, O. ;
- Heitz, F. ;
- Freudenberger, M. ;
- Bensmann, E. ;
- DuBois, A. ;
- Nitz, U. ;
- Pelz, E. ;
- Warm, M. ;
- Ortmann, M. ;
- Sultova, E. ;
- Brucker, S.Y. ;
- Kates, R.E. ;
- Fehm, T. ;
- Harbeck, N.